Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

NCT06550011 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular (Wet) AMD

Interventions

DRUG: ABI-110 Low Dose
DRUG: ABI-110 Medium Dose
DRUG: ABI-110 High Dose

Sponsor

Avirmax Biopharma Inc